Serdexmethylphenidate/dexmethylphenidate
Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a fixed-dose combination medication containing serdexmethylphenidate and dexmethylphenidate which is used to treat attention deficit hyperactivity disorder (ADHD) in people aged six years and older.[2][3]
 | |
 | |
| Combination of | |
|---|---|
| Serdexmethylphenidate | Prodrug of dexmethylphenidate |
| Dexmethylphenidate | Catecholamine reuptake inhibitor |
| Clinical data | |
| Trade names | Azstarys |
| Other names | KP415 |
| AHFS/Drugs.com | Azstarys |
| License data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
It was approved for medical use in the United States in March 2021.[2]
References
- "Azstarys- serdexmethylphenidate and dexmethylphenidate capsule". DailyMed. Retrieved 13 July 2021.
- "KemPharm Announces FDA Approval of Azstarys (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD" (Press release). KemPharm. 3 March 2021. Retrieved 3 March 2021 – via GlobeNewswire.
- McCuistion LE, Yeager JJ, Winton MB, DiMaggio K (2021). "Chapter 18: Stimulants". Pharmacology E-Book: A Patient-Centered Nursing Process Approach. St. Louis, MO: Elsevier Health Sciences. p. 203. ISBN 978-0-323-79316-2.
External links
- "Serdexmethylphenidate". Drug Information Portal. U.S. National Library of Medicine.
- "Dexmethylphenidate". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.